{"id":"NCT02773576","sponsor":"Braeburn Pharmaceuticals","briefTitle":"Safety and Tolerability of Risperidone Implants","officialTitle":"A One Year, Open-label, Study to Evaluate the Safety and Tolerability of Risperidone Implants as a Maintenance Treatment in Patients With Schizophrenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-04","primaryCompletion":"2017-09","completion":"2017-09","firstPosted":"2016-05-16","resultsPosted":"2020-02-19","lastUpdate":"2020-02-19"},"enrollment":140,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"Risperidone implant","otherNames":[]}],"arms":[{"label":"2x360 mg risperidone implant","type":"EXPERIMENTAL"},{"label":"3x300 mg risperidone implant","type":"EXPERIMENTAL"}],"summary":"A one year, open-label, study to evaluate the safety and tolerability of risperidone implants as a maintenance treatment in patients with schizophrenia","primaryOutcome":{"measure":"Number of Participants With Treatment-related Adverse Events as Assessed","timeFrame":"12 months","effectByArm":[],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":0},"commonTop":[]}}